All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and product pipeline which includes company’s lead glaucoma asset as well as its products for dry eye, allergy, and other anterior segment conditions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2020
Details:
The collaboration will research and develop an extended delivery formulation of aflibercept via the suprachoroidal space.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV vectors gene therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Harvard University
Deal Size: $2000.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 11, 2020
Details:
CapsidMap™ enables the design of novel Adeno-Associated Virus (AAV) vectors that significantly improve upon current approaches to gene therapy and expand the scope of accessible diseases.